Voordes, Geert H. D. published the artcileThe interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function, Category: amides-buliding-blocks, the publication is European Journal of Heart Failure (2022), 24(5), 804-806, database is CAplus and MEDLINE.
A review. This article refers to ‘Effects of sacubitril/valsartan vs. valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF’ by A. Peikert et al. , published in this issue on pages 794-803. Two important clin. points can be taken from this study. First, based on the available data sacubitril/valsartan has a similar renoprotective effect in patients with HFpEF with and without DM. Second, sacubitril/valsartan might represent a valuable treatment option for patients with HFpEF and diabetes to attenuate kidney function decline.
European Journal of Heart Failure published new progress about 137862-53-4. 137862-53-4 belongs to amides-buliding-blocks, auxiliary class GPCR/G Protein,Angiotensin Receptor, name is (S)-2-(N-((2′-(1H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid, and the molecular formula is C9H5ClO4S, Category: amides-buliding-blocks.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics